Jasper Therapeutics (JSPR) Competitors $3.14 -0.13 (-3.98%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. NMRA, FDMT, NLTX, EPRX, VTYX, OGI, SLS, YMAB, ALMS, and CTMXShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Neumora Therapeutics (NMRA), 4D Molecular Therapeutics (FDMT), Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Ventyx Biosciences (VTYX), Organigram Global (OGI), SELLAS Life Sciences Group (SLS), Y-mAbs Therapeutics (YMAB), Alumis (ALMS), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Its Competitors Neumora Therapeutics 4D Molecular Therapeutics Neoleukin Therapeutics Eupraxia Pharmaceuticals Ventyx Biosciences Organigram Global SELLAS Life Sciences Group Y-mAbs Therapeutics Alumis CytomX Therapeutics Neumora Therapeutics (NASDAQ:NMRA) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends. Do insiders and institutionals hold more shares of NMRA or JSPR? 47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, NMRA or JSPR? Neumora Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$243.79M-$1.61-1.24Jasper TherapeuticsN/AN/A-$71.27M-$5.24-0.60 Do analysts rate NMRA or JSPR? Neumora Therapeutics currently has a consensus price target of $7.14, suggesting a potential upside of 258.04%. Jasper Therapeutics has a consensus price target of $29.75, suggesting a potential upside of 847.45%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Neumora Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22Jasper Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk & volatility, NMRA or JSPR? Neumora Therapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500. Does the media prefer NMRA or JSPR? In the previous week, Jasper Therapeutics had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for Jasper Therapeutics and 4 mentions for Neumora Therapeutics. Jasper Therapeutics' average media sentiment score of 0.22 beat Neumora Therapeutics' score of 0.16 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is NMRA or JSPR more profitable? Neumora Therapeutics' return on equity of -84.79% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -84.79% -77.57% Jasper Therapeutics N/A -109.45%-89.82% SummaryJasper Therapeutics beats Neumora Therapeutics on 8 of the 13 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.16M$3.06B$5.67B$9.49BDividend YieldN/A2.44%4.05%3.99%P/E Ratio-0.6020.7227.8919.99Price / SalesN/A249.89396.7582.82Price / CashN/A41.9636.1958.45Price / Book0.768.288.645.82Net Income-$71.27M-$55.19M$3.24B$258.39M7 Day Performance-6.82%4.80%3.11%2.05%1 Month Performance-43.63%17.28%10.58%12.16%1 Year Performance-84.87%6.75%34.89%20.90% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics3.744 of 5 stars$3.14-4.0%$29.75+847.5%-84.8%$47.16MN/A-0.6020NMRANeumora Therapeutics2.51 of 5 stars$1.27-1.6%$7.50+490.6%-84.5%$205.42MN/A-0.79108News CoverageGap UpFDMT4D Molecular Therapeutics2.3132 of 5 stars$4.38+2.3%$29.56+574.8%-73.7%$202.93M$40K-1.38120News CoverageNLTXNeoleukin TherapeuticsN/A$21.43-2.4%N/A-48.1%$201.40MN/A-6.8990News CoverageHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.4908 of 5 stars$5.59+4.3%$11.00+96.8%+97.8%$201.02MN/A-7.3629News CoverageAnalyst ForecastGap UpVTYXVentyx Biosciences3.4914 of 5 stars$2.81+2.6%$10.00+255.9%+10.1%$199.96MN/A-1.6130OGIOrganigram Global0.6691 of 5 stars$1.48+2.1%N/A-11.7%$198.23M$117.47M14.80860SLSSELLAS Life Sciences Group1.644 of 5 stars$1.98+7.6%N/A+56.6%$197.56M$1M-5.2110YMABY-mAbs Therapeutics3.1349 of 5 stars$4.36flat$15.60+257.8%-62.5%$197.42M$87.68M-6.81150News CoverageALMSAlumis3.2417 of 5 stars$3.60+2.3%$22.86+534.9%-69.5%$195.88MN/A0.00N/ANews CoverageCTMXCytomX Therapeutics3.7895 of 5 stars$2.39-1.2%$5.33+123.2%+68.8%$192.68M$138.10M4.98170 Related Companies and Tools Related Companies Neumora Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Neoleukin Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Ventyx Biosciences Alternatives Organigram Global Alternatives SELLAS Life Sciences Group Alternatives Y-mAbs Therapeutics Alternatives Alumis Alternatives CytomX Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPR Stock Alerts